CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 500 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01083186
NCT01083186N/ACompleted
CompareCT.gov

Paricalcitol Oral Therapy in Predialysis CKD Patients. The Greek Experience

AbbVie (prior sponsor, Abbott)·observational·Posted Mar 9, 2010·Updated Mar 12, 2013

In Brief

An observational study for Chronic Kidney Failure and Secondary Hyperparathyroidism. Completed, enrolled 500 participants across 24 sites.

Detailed Summary

The purpose of this study is to obtain data on the use of Zemplar (paricalcitol) capsules in real-life clinical practice in predialysis patients with chronic kidney disease (CKD) and secondary hyperparathyroidism.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Failure, Secondary Hyperparathyroidism
CountriesGreece
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 9, 2010
Enrollment StartJun 1, 2009
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 16.3 years ago